Skip to content
Open access

Differential Cardiometabolic Risk Profiles of Lean and Obese Metabolic Dysfunction-Associated Steatotic Liver Disease: A Longitudinal Health Checkup Cohort Study.

Oct 2026 · Hepatology Research · 0 citations · 14 references
Medicine

TL;DR

Lean MASLD shared a broadly similar cardiometabolic risk structure with Obese MASLD, whereas the relative contribution of risk factors differed between phenotypes, providing exploratory evidence of phenotype-specific metabolic associations requiring validation before clinical application.

Abstract

Background

Lean metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized. Whether it represents a distinct entity or a phenotype within the MASLD spectrum remains unclear. We examined differences in risk factor contribution and metabolic trajectories.

Methods

In a longitudinal health checkup cohort (2017-2025), we included individuals without hepatic steatosis at baseline and excluded those with alcohol intake at or above the MetALD threshold. Incident MASLD was classified at diagnosis as Obese or Lean MASLD based on obesity status (BMI/WC). Baseline risk factors were evaluated using time-to-event and competing-risk models with interaction testing. Longitudinal metabolic changes were assessed using logistic regression, and repeated trajectories were examined using linear mixed-effects models.

Results

Among 13,624 participants, 1865 developed incident MASLD (Obese MASLD, n = 1469; Lean MASLD, n = 396). Male sex, baseline obesity, glycemic abnormality/diabetes, hypertension, hypertriglyceridemia, and higher baseline ALT were independently associated with incident MASLD. Interaction analyses showed a stronger contribution of male sex and weaker contributions of hypertension and low HDL-C in Lean MASLD. Longitudinal analyses showed Δtriglycerides and ΔALT were consistently associated with incident MASLD in both phenotypes, whereas ΔBMI showed a stronger association with Obese MASLD.

Conclusions

Lean MASLD shared a broadly similar cardiometabolic risk structure with Obese MASLD, whereas the relative contribution of risk factors differed between phenotypes. Male sex showed a stronger association with Lean MASLD, whereas longitudinal changes in triglycerides and ALT were consistently associated with incident MASLD across both phenotypes. These findings provide exploratory evidence of phenotype-specific metabolic associations requiring validation before clinical application.

Read PDF

Similar papers

Open access Oct 2026

Genetic and Body Composition Factors Associated with Metabolic-Associated Steatotic Liver Disease: A Cross-Sectional Analysis of a Health Screening Cohort

Introduction Metabolic-associated steatotic liver disease (MASLD), newly defined in 2023, is characterized by excessive hepatic triglyceride accumulation in the presence of cardiometabolic risk factors. The body roundness index (BRI), an indicator of body fat distribution and visceral adiposity, has been proposed as a...

Yi-Hsuan Shen, Yi-Chen Lee, Tzu-Jung Chou et al. · 0 citations
Review Oct 2026

Metabolic Burden, Metabolic Dysfunction-Associated Steatotic Liver Disease, and Cognitive Performance Among Older Adults: Analysis of 1,387 Participants from the National Health and Nutrition Examination Survey.

BACKGROUND Metabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent in older adults, yet its independent contribution to cognitive decline beyond cardiometabolic risk factors remains uncertain. METHODS We performed a cross-sectional analysis of 1,387 NHANES 2011-2014 participants aged ≥60 years....

Mohammad Aldiabat, Yazan Aljabiri, Wesam Aleyadeh et al. · 0 citations
Review Open access Sep 2026

A cardiometabolic risk phenotype index integrating insulin resistance, systemic inflammation, and psychological burden for mortality risk stratification in metabolic dysfunction-associated steatotic liver disease: an exploratory longitudinal analysis of a nationally representative cohort

The ISP index was positively associated with the risks of ACM and CVM among individuals with MASLD, but because it was constructed and internally evaluated within the same sample, its apparent predictive performance may be optimistic owing to overfitting.

Yan Chen, Kai-Ling Xie, Ning-Kun Xiao et al. · 0 citations
Open access Oct 2026

Association of cumulative triglyceride-glucose index with incident metabolic dysfunction-associated steatotic liver disease: a cohort study

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global public health burden with progressive hepatic and cardiometabolic consequences. Insulin resistance is central to MASLD pathogenesis, and the triglyceride-glucose (TyG) index is a practical surrogate marker for insulin resistance...

S. Kang, N. Zhang, W. Chen et al. · 0 citations
Open access Sep 2026

Association between body composition and metabolic dysfunction-associated steatotic liver disease in Chinese general population: a cross-sectional study stratified by sex and obesity status

FFM/FM ratio shows a universal protective effect against MASLD across sex and obesity strata, while WHR has sex-specific predictive value only in women.

Xia Tan, Xiao-Min Hou, Yuan Wen et al. · 0 citations
Oct 2026

Normal-BMI MASLD is Associated with Increased Mortality, Cardiovascular Events, Cancer and Lower GLP-1 Use.

BACKGROUND Metabolic dysfunction-associated steatotic liver disease (MASLD) can occur in individuals who are not overweight or have obesity (normal-BMI MASLD), yet disease burden and management remain poorly characterized. We compared long-term outcomes and incretin-based therapy use between normal-BMI MASLD (nbMASLD)...

Isabel Casimiro, Aoi Agawa, Rachel Haide N. Tacata et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.